FOLH1 and prostate carcinoma: This prospective referring physician–based survey shows a significant impact (54/101; 53%) of 68Ga-PSMA-11 PET/CT on the actual management of prostate cancer patients with BCR. Importantly, intended management changes after 68Ga-PSMA-11 PET/CT were further modified in almost 50% of the patients, underlining the limitations of survey-based management assessment